A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain

Scott R Evans, David M Simpson, Douglas W Kitch, Agnes King, David B Clifford, Bruce A Cohen, Justin C McArthur, Neurologic AIDS Research Consortium, AIDS Clinical Trials Group, Burk Jubelt, Norman Latov, Howard Gendelman, David Glidden, Mike Nunn, Peter Gilbert, Kay Carter, Diane Thomas, Elyse Singer, Mallory Witt, Ruben Lopez-Apodaca, Richard K Olney, Jeffrey W Ralph, Joseph C Gathe, Ataher Syed, Bruce Cohen, Linda Reisberg, Taryn Exter, Kathleen Nuffer, Mary Gould, Teresa Spitz, Michael S Somero, Kelly A Morris, Michael Somero, Daniel Feinberg, Pablo Tebas, Susama Verma, Vilma M Vega, Mauricio Concha, Jose G Castro, Lillian Colon, Yuen So, Debbie Slamowitz, Trevor Hawkins, Wenoah Veikley, Giovanni Schifitto, Carol Greisberger, Michael Rubin, Ivanka Zaprianova, Ramon Diaz-Arrastia, Tianna Petersen, Daniel J Skiest, Tim Sumarll, Tani Ginebra, Moraima Rivera, Yunanan Mootoor, Julie Gurwell, Ronald G Nahass, Scott R Evans, David M Simpson, Douglas W Kitch, Agnes King, David B Clifford, Bruce A Cohen, Justin C McArthur, Neurologic AIDS Research Consortium, AIDS Clinical Trials Group, Burk Jubelt, Norman Latov, Howard Gendelman, David Glidden, Mike Nunn, Peter Gilbert, Kay Carter, Diane Thomas, Elyse Singer, Mallory Witt, Ruben Lopez-Apodaca, Richard K Olney, Jeffrey W Ralph, Joseph C Gathe, Ataher Syed, Bruce Cohen, Linda Reisberg, Taryn Exter, Kathleen Nuffer, Mary Gould, Teresa Spitz, Michael S Somero, Kelly A Morris, Michael Somero, Daniel Feinberg, Pablo Tebas, Susama Verma, Vilma M Vega, Mauricio Concha, Jose G Castro, Lillian Colon, Yuen So, Debbie Slamowitz, Trevor Hawkins, Wenoah Veikley, Giovanni Schifitto, Carol Greisberger, Michael Rubin, Ivanka Zaprianova, Ramon Diaz-Arrastia, Tianna Petersen, Daniel J Skiest, Tim Sumarll, Tani Ginebra, Moraima Rivera, Yunanan Mootoor, Julie Gurwell, Ronald G Nahass

Abstract

Objectives: To examine the efficacy and safety of Prosaptide (PRO) for the treatment of painful HIV-associated sensory neuropathies (HIV-SN).

Design: A randomized, double-blind, placebo-controlled, multicenter study in participants with sensory neuropathy. Pain modulating therapy was discontinued prior to baseline. Participants were stratified by sural sensory nerve action potential (SNAP) amplitude. Participants were trained to use an electronic diary (ED) to record pain.

Setting: Peripheral neuropathies are common complications of HIV infection. The pathogenesis is unknown and currently treatments are restricted to symptomatic measures. We examined PRO against placebo (PBO) for treatment of painful HIV-SN and performed a post-hoc evaluation of an electronic diary (ED) to record HIV-associated neuropathic pain.

Participants: Eligible participants included adults with neurologist-confirmed painful HIV-SN.

Interventions: 2, 4, 8, or 16 mg/d PRO or PBO administered via subcutaneous (SC) injection for six weeks. Neurotoxic antiretroviral drug usage was held constant.

Outcome measures: Changes from baseline in the weekly average of evaluable daily random prompts measuring pain using the Gracely pain scale and adverse events.

Results: 237 participants were randomized. The study was stopped after a planned futility analysis. There were no between-group differences in the frequency of adverse events or laboratory toxicities. The 6-week mean (sd) Gracely pain scale changes were -0.12 (0.23), -0.24 (0.35), -0.15 (0.32), -0.18 (0.34), and -0.18 (0.32) for the 2, 4, 8, 16 mg, and PBO arms respectively. A similar variability of pain changes recorded using the ED were noted compared to previous trials that used paper collection methods.

Conclusions: 6-week treatment with PRO was safe but not effective at reducing HIV-associated neuropathic pain. Use of an ED to record neuropathic pain is novel in HIV-SN, resulted in reasonable compliance in recording pain data, but did not decrease the variability of pain scores compared to historical paper collection methods.

Trial registration: Current Controlled Trials NCT00286377.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. CONSORT Diagram.
Figure 1. CONSORT Diagram.
Figure 2. Difference of Mean Gracely Pain…
Figure 2. Difference of Mean Gracely Pain Score Changes (Using LOCF) between each Dosing Group and Placebo across Weeks.

References

    1. Sacktor N, Lyles R, Skolasky R, Kleeberger C, Selnes OA, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study. Neurology. 2001;56:257–260.
    1. Bacellar H, Munoz A, Miller EN, Cohen BA, Besley D, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985–1992. Neurology. 1984;44:1892–1900.
    1. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurology. 2005;4(9):543–555.
    1. Wulff E, Wang A, Simpson D. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs. 2000;59:1251–1260.
    1. Cornblath D, McArthur J. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology. 1988;1938:794–796.
    1. Barohn RJ, Gronseth GS, LeForce BR, McVey AL, McGuire SA, Butzin CA. Peripheral nervous system involvement in a large cohort of human immunodeficiency virus-infected individuals. Arch Neurol. 1993;50:167–171.
    1. Griffin JWCT, McArthur JC. In: Peripheral neuropathies associated with HIV infection. The Neurology of AIDS. Gendelman HELS, Epstein L, Swindells S, editors. New York: Chapman & Hall; 1998. pp. 275–291.
    1. Brinkman K, Hofstede J, Burger D, Smeitink J, Koopmans P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998;12:1735–1744.
    1. Brew BJ, Tisch S, Law M. Lactate concentrations distinguish between nucleoside neuropathy and HIV neuropathy. AIDS. 2003;17(7):1094–1096.
    1. Cherry CL, Gahan ME, McArthur J, Lwein SR, Hoy JF, et al. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. JAIDS. 2002;30:271–277.
    1. Keswani SC, Carlos A, Pardo CA, Cherry CL, Hoke A, McArthur JC. HIV-associated sensory neuropathies. AIDS. 2002;16:2105–2117.
    1. Mizisin A, Steinhardt R, O'Brien J, Calcutt N. TX14(A), a prosaposin-derived peptide, reverses established nerve disorders in streptozotocin-diabetic rats and prevents them in glalactose-fed rats. J Neuropathol Exp Neurol. 2001;60:953–960.
    1. Calcutt N, Freshwater J, O'Brien J. Protection of sensory function and antihyperalgesic properties of prosaposin-derived peptide in diabetic rats. Anesthesiology. 2000;93:1271–1278.
    1. Otero D, Conrad B, O'Brien J. Reversal of thermal hyperalgesia in a rat partial sciatic nerve ligation model of Prosaptide TX14(A). Neurosci Lttrs. 1999;270:29–32.
    1. Wagner R, Myers R, O'Brien J. Prosaptide prevents hyperalgesia and reduces peripheral TNFR1 expression following TNF-alfa nerve injection. Neuroreport. 1998;9:2827–2831.
    1. Calcutt NA, Campana WM, Eskeland NL, Mohiuddin L, Dines KC, et al. Prosaposin gene expression and the efficacy of a prosaposin-derived peptide in preventing structural and functional disorders of peripheral nerve in diabetic rats. J Neuropathol Exp Neurol. 1999;58:628–636.
    1. Campana W, Eskeland N, Calcutt N, Misasi R, Myers R, et al. Prosaptide prevents paclitaxel neurotoxicity. Neuro Tox. 1998;19:237–244.
    1. Janssen RS, Cornblath DR, Epstein LG, Foa RP, McArthur JC, Price RW, et al. Nomenclature and research case definitions for neurological manifestations of human immunodeficiency virus type-1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology. 1991;41:778–785.
    1. McArthur JC, Yiannoutsos C, Simpson D, Adornato B, Singer EJ, et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. Neurology. 2000;54(5):1080–1088.
    1. Kieburtz K, Simpson D, Yiannoutsos C, Max MB, Hall CD, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. Neurology. 1998;51(6):1682–1688.
    1. Wei LJ, Johnson W. Combining dependent tests with incomplete repeated measurements. Biometrika. 1985;72:359–364.
    1. Simpson DM, McArthur JC, Olney R, Clifford D, So Y, Ross D, Baird BJ, Barrett P, Hammer AE. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology. 2003;60(9):1508–14.
    1. Bacellar H, Munoz A, Miller EN, Cohen BA, Besley D, Selnes OA, Becker JT, McArthur JC. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985–1992. Neurology. 1994;44(10):1892–900.
    1. Pettersen JA, Jones G, Worthingon C, Krentz HB, Keppler OT, Hoke A, Gill MJ, Power C. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol. 2006;59:816–824.
    1. Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient non-compliance with paper diaries. Brit Med J. 2002;324(7347):1193–1194.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅